Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Payables: 2020-2025

Historic Payables for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to $103.5 million.

  • Tarsus Pharmaceuticals' Payables rose 89.75% to $103.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.3 million, marking a year-over-year increase of 104.20%. This contributed to the annual value of $64.8 million for FY2024, which is 173.48% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Payables is $103.5 million, which was up 31.61% from $78.6 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Payables peaked at $103.5 million during Q3 2025, and registered a low of $8.1 million during Q3 2021.
  • Moreover, its 3-year median value for Payables was $43.5 million (2024), whereas its average is $46.9 million.
  • Its Payables has fluctuated over the past 5 years, first dropped by 16.25% in 2023, then skyrocketed by 360.15% in 2024.
  • Tarsus Pharmaceuticals' Payables (Quarterly) stood at $8.7 million in 2021, then increased by 14.17% to $9.9 million in 2022, then spiked by 139.06% to $23.7 million in 2023, then soared by 173.48% to $64.8 million in 2024, then soared by 89.75% to $103.5 million in 2025.
  • Its Payables was $103.5 million in Q3 2025, compared to $78.6 million in Q2 2025 and $76.4 million in Q1 2025.